ATAI ATAI LIFE SCIENCES BV

atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) --  (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October 11-12, 2023.

Details of the company’s participation is as follows:

Jefferies Inaugural Biotech CNS/Neuro Summit

Format: Fireside Chat

Date and Time: Wednesday, October 11th at 8:30 A.M. ET

Location: New York, NY

A webcast of the company’s fireside chat will be available on atai’s website under Events on the Investors section of the atai website: . A replay will be available following the live event.

About atai Life Sciences



atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and was founded as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients.

atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit .

Contact Information

Investor Contact:

Media Contact:



EN
06/10/2023

Underlying

ATAIATAI LIFE SCIENCES BV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ATAI LIFE SCIENCES BV

 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthenin...

AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio NEW YORK and AMSTERDAM, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that the United States Patent and Trademark Office has granted a new patent covering EMP-01 (oral R-MDMA), further strengthening the company’s intellectual property estate and long-term...

December 11, 2025 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley to Participate in the Jefferies Global Healthcare Conferen...

AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London NEW YORK and AMSTERDAM, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that Srinivas Rao, M.D., Ph.D., Co-Founder and Chief Executive Officer, and Kevin Craig, M.D., Chief Medical Officer, are scheduled to participate in the Jefferies Global Healthcare Conference in London, UK. De...

November 13, 2025 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Co...

AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights AtaiBeckley solidifies position as a global leader in transformative mental health therapies with a short psychedelic duration BPL-003 (mebufotenin benzoate nasal spray) granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression (TRD) Reported positive topline data from the Phase 2b open-label extension (OLE) study of BPL-003 showing the potential added and sustained antidepressant effects following a second dose in patients with TRD Repo...

November 12, 2025 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Lab...

AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression A 12 mg dose of BPL-003 (mebufotenin benzoate nasal spray) administered eight weeks after an initial 12 mg, 8 mg or 0.3 mg dose in the core study of the Phase 2b clinical trial produced additional rapid, clinically meaningful antidepressant effects that were sustained for up to eight weeksPatients who received an active dose of BPL-003 in the core study of the Phase 2b clinical trial (either 8 mg ...

November 10, 2025 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences and Beckley Psytech Announce the Successful Complet...

atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies atai Life Sciences’ shareholders voted to approve the strategic combination with Beckley Psytech Limited and the corporate redomiciliation at the Extraordinary General Meeting of Shareholders on November 4, 2025, with approximately 98% of the votes cast at the Extraordinary General Meeting in favor of the transactionsAtaiBeckley has an industry-leading pipeline of investigational treatments, led by BPL-003 (...

November 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch